Stephen Johnston1, Mark Basik2, Roberto Hegg3, Wirote Lausoontornsiri4, Lukasz Grzeda5, Mark Clemons6, Lydia Dreosti7, Helen Mann8, Mary Stuart8, Massimo Cristofanilli9. 1. The Royal Marsden NHS Foundation Trust, The Royal Marsden Hospital, Fulham Road, Chelsea, London, SW3 6JJ, UK. Stephen.Johnston@rmh.nhs.uk. 2. Jewish General Hospital, Montreal, Canada. 3. Hospital Perola Byington, São Paulo, Brazil. 4. National Cancer Institute of Thailand, Bangkok, Thailand. 5. Magodent Sp. z o.o. Grupa Lux Med, Warsaw, Poland. 6. The Ottawa Hospital Cancer Center, Ottawa, Canada. 7. University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa. 8. AstraZeneca, Macclesfield, UK. 9. Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Abstract
PURPOSE:AZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II MINT study (ClinicalTrials.gov NCT01151215) investigated whether adding AZD8931 to endocrine therapy would delay development of endocrine resistance in patients with hormone-sensitive advanced breast cancer. METHODS: Patients were randomized 1:1:1 to receive daily anastrozole (1 mg) in combination with AZD8931 20 mg twice daily (bid), AZD8931 40 mg bid, or placebo. The primary objective was evaluation of progression-free survival (PFS) in patients treated with combination AZD8931 and anastrozole versus anastrozole alone. Secondary objectives included assessment of safety and tolerability, objective response rate, and overall survival. RESULTS: At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event. Median PFS (HR; 95 % CI vs placebo) in the AZD8931 20, 40 mg, and placebo arms was 10.9 (1.37; 0.91-2.06, P = 0.135), 13.8 (1.16; 0.77-1.75, P = 0.485), and 14.0 months, respectively. No indication of clinical benefit was observed following treatment with AZD8931 for the secondary endpoints. Safety findings showed a greater incidence of diarrhea (40, 51, and 12 % for AZD8931 20, 40 mg, and placebo, respectively), rash (32, 48, and 12 %), dry skin (19, 25, and 2 %), and acneiform dermatitis (16, 28, and 2 %) in patients treated with AZD8931 versus placebo. CONCLUSIONS:AZD8931, in combination with endocrine therapy, does not appear to enhance endocrine responsiveness and is associated with greater skin and gastrointestinal toxicity.
RCT Entities:
PURPOSE:AZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II MINT study (ClinicalTrials.gov NCT01151215) investigated whether adding AZD8931 to endocrine therapy would delay development of endocrine resistance in patients with hormone-sensitive advanced breast cancer. METHODS:Patients were randomized 1:1:1 to receive daily anastrozole (1 mg) in combination with AZD8931 20 mg twice daily (bid), AZD8931 40 mg bid, or placebo. The primary objective was evaluation of progression-free survival (PFS) in patients treated with combination AZD8931 and anastrozole versus anastrozole alone. Secondary objectives included assessment of safety and tolerability, objective response rate, and overall survival. RESULTS: At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event. Median PFS (HR; 95 % CI vs placebo) in the AZD8931 20, 40 mg, and placebo arms was 10.9 (1.37; 0.91-2.06, P = 0.135), 13.8 (1.16; 0.77-1.75, P = 0.485), and 14.0 months, respectively. No indication of clinical benefit was observed following treatment with AZD8931 for the secondary endpoints. Safety findings showed a greater incidence of diarrhea (40, 51, and 12 % for AZD8931 20, 40 mg, and placebo, respectively), rash (32, 48, and 12 %), dry skin (19, 25, and 2 %), and acneiform dermatitis (16, 28, and 2 %) in patients treated with AZD8931 versus placebo. CONCLUSIONS:AZD8931, in combination with endocrine therapy, does not appear to enhance endocrine responsiveness and is associated with greater skin and gastrointestinal toxicity.
Authors: Ricardo Ribas; Sunil Pancholi; Aradhana Rani; Eugene Schuster; Stephanie K Guest; Joanna Nikitorowicz-Buniak; Nikiana Simigdala; Allan Thornhill; Francesca Avogadri-Connors; Richard E Cutler; Alshad S Lalani; Mitch Dowsett; Stephen R Johnston; Lesley-Ann Martin Journal: Breast Cancer Res Date: 2018-06-08 Impact factor: 6.466
Authors: Richard Adams; Ewan Brown; Louise Brown; Rachel Butler; Stephen Falk; David Fisher; Richard Kaplan; Phil Quirke; Susan Richman; Leslie Samuel; Jenny Seligmann; Matt Seymour; Kai Keen Shiu; Harpreet Wasan; Richard Wilson; Tim Maughan Journal: Lancet Gastroenterol Hepatol Date: 2017-12-16
Authors: Anne Thomas; Pradeep S Virdee; Martin Eatock; Simon R Lord; Stephen Falk; D Alan Anthoney; Richard C Turkington; Matthew Goff; Leena Elhussein; Linda Collins; Sharon Love; Joanna Moschandreas; Mark R Middleton Journal: Eur J Cancer Date: 2019-11-22 Impact factor: 9.162
Authors: Matthew F Peters; Tim Landry; Carmen Pin; Kim Maratea; Cortni Dick; Matthew P Wagoner; Allison L Choy; Herb Barthlow; Deb Snow; Zachary Stevens; Alex Armento; Clay W Scott; Seyoum Ayehunie Journal: Toxicol Sci Date: 2019-03-01 Impact factor: 4.849